Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Published:2023-07-27 Issue:4 Volume:389 Page:335-347
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

San-Miguel Jesús¹,Dhakal Binod¹^ORCID,Yong Kwee¹,Spencer Andrew¹,Anguille Sébastien¹,Mateos María-Victoria¹,Fernández de Larrea Carlos¹,Martínez-López Joaquín¹,Moreau Philippe¹,Touzeau Cyrille¹,Leleu Xavier¹,Avivi Irit¹,Cavo Michele¹,Ishida Tadao¹,Kim Seok Jin¹,Roeloffzen Wilfried¹,van de Donk Niels W.C.J.¹,Dytfeld Dominik¹,Sidana Surbhi¹,Costa Luciano J.¹^ORCID,Oriol Albert¹,Popat Rakesh¹,Khan Abdullah M.¹,Cohen Yaël C.¹,Ho P. Joy¹,Griffin James¹,Lendvai Nikoletta¹,Lonardi Carolina¹,Slaughter Ana¹,Schecter Jordan M.¹,Jackson Carolyn C.¹,Connors Kaitlyn¹,Li Katherine¹,Zudaire Enrique¹,Chen Diana¹,Gilbert Jane¹,Yeh Tzu-min¹,Nagle Sarah¹,Florendo Erika¹,Pacaud Lida¹,Patel Nitin¹,Harrison Simon J.¹,Einsele Hermann¹

Affiliation:

1. From the Cancer Center Clínica Universidad de Navarra, Centro Investigación Medica Aplicada, Instituto de Investigación de Navarra, Centro Investigación Biomédica en Red Cáncer (CIBERONC), Pamplona (J.S.-M.), the University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), the Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer,...

Funder

Janssen Research & Development, LLC

Legend Biotech USA Inc.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2303379

Reference26 articles.

1. Sequencing multiple myeloma therapies with and after antibody therapies

2. Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period